89bio to participate in the svb securities global biopharma conference

San francisco, feb. 08, 2023 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the svb securities global biopharma conference on wednesday, february 15, 2023 at 12:00 pm et.
ETNB Ratings Summary
ETNB Quant Ranking